Document Detail

Current approaches to the use of sirolimus in renal transplantation.
MedLine Citation:
PMID:  19857664     Owner:  NLM     Status:  In-Process    
Sirolimus, a macrolide with immunosuppressive properties, was introduced into clinical practice a decade ago. The optimal use of this drug remains controversial: It displays a wide range of organ and tissue toxicities owing to the critical role of its therapeutic site- the kinase mammalian target of rapamycin-in the signal transduction pathways of numerous cytokines, growth factors, hormones, and nutrients. However, it displays unique, recognized benefits for renal transplant recipients: synergistic interactions with cyclosporine and possibly tacrolimus, allowing marked reduction in exposure to the calcineurin inhibitor; reduction in the frequency of posttransplant malignancies, particularly lymphomas, Kaposi sarcomas, and hypernephromas; and modest nephrotoxicity in comparison with calcineurin inhibitors. Because of its inhibitory effects on endothelial and smooth muscle cell proliferation, sirolimus may be a useful tool to dampen chronic vasculo-obliterative processes that attenuate graft survival. With increasing experience with the drug, the true potential of sirolimus will be realized to be a critical element in the immunosuppressive matrix.
B D Kahan
Related Documents :
12748354 - Incidence of polyomavirus-nephropathy in renal allografts: influence of modern immunosu...
11558484 - Replacement of calcineurin inhibitors with mycophenolate mofetil in liver-transplant pa...
16364864 - Itraconazole prophylaxis in lung transplant recipients receiving tacrolimus (fk 506): e...
17516874 - Compared benefit of approved and experimental immunosuppressive therapeutic approaches ...
8897514 - Histopathology of bone marrow after allogeneic bone marrow transplantation for chronic ...
19246724 - Assessment of the effects of renal impairment on the pharmacokinetic profile of fesoter...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Transplantation proceedings     Volume:  41     ISSN:  1873-2623     ISO Abbreviation:  Transplant. Proc.     Publication Date:  2009 Oct 
Date Detail:
Created Date:  2009-10-27     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0243532     Medline TA:  Transplant Proc     Country:  United States    
Other Details:
Languages:  eng     Pagination:  3011-5     Citation Subset:  IM    
Department of Surgery University of Texas, Division of Immunology and Organ Transplantation, 6431 Fannin, MSB 6240, Houston, TX 77030, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Multidrug resistance-associated protein 2 gene (ABCC2) variant in kidney allograft recipients.
Next Document:  Safety and tolerance of sodium mycophenolate in patients after renal transplantation--an observation...